Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

U.S. researchers identify muscarinic M4 receptor antagonists

Oct. 9, 2020

NOD1 as a potential new therapeutic target for saturated-fat induced insulin resistance

Oct. 8, 2020

Pharmacokinetic data on AbFero's iron chelator SP-420 support planned phase I/II study

Oct. 7, 2020

Avrobio licenses gene therapy for Hunter's syndrome from University of Manchester

Oct. 7, 2020

Gut-derived LEAP2 fragment demonstrates beneficial metabolic effects on RYGB

Oct. 7, 2020

Fulcrum Therapeutics discovers new EED inhibitors

Oct. 7, 2020

Kyushu University presents new lysosomal alpha-glucosidase inhibitors

Oct. 6, 2020

Ovoca's BP-101 for decreased sexual desire in women not approved in Russia

Oct. 5, 2020

European Commission approves Crysvita for adolescents and adults with XLH

Oct. 5, 2020

IntraBio's multinational trial of IB-1001 in Niemann-Pick disease type C meets primary endpoint

Oct. 2, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...